Literature DB >> 21615435

Review article: defining remission in ulcerative colitis.

S P L Travis1, P D R Higgins, T Orchard, C J Van Der Woude, R Panaccione, A Bitton, C O'Morain, J Panés, A Sturm, W Reinisch, M A Kamm, G D'Haens.   

Abstract

BACKGROUND: There is no international agreement on scoring systems used to measure disease activity in ulcerative colitis, nor is there a validated definition for disease remission. AIM: To review the principles and components for defining remission in ulcerative colitis and propose a definition that will help improve patient outcomes.
METHODS: A review of current standards of remission from the perspective of clinical trials, guidelines, clinical practice and patients was conducted by the authors. Selected literature focused on the components of a definition of remission, the utility of a definition and treatment strategies, based on current definitions.
RESULTS: Different definitions of remission affect the assessment of outcome and make it difficult to compare trials. In the clinic, endoscopy is rarely used to confirm remission, because mucosal healing has only recently begun to be related to the duration of subsequent remission in a way that will affect clinical practice. Histopathology may be the ultimate arbiter of mucosal healing. There is no agreement on the definition of remission in current guidelines. Patient-defined remission may predict endoscopic remission, but has yet to be shown to predict duration of remission.
CONCLUSIONS: A standard based on clinical symptoms and endoscopy is proposed. Histopathology is a third dimension of remission that may have prognostic value. The definition of remission should help predict long-term outcome. The expectations of patients and their physicians need to be raised, as the goal of treatment of active ulcerative colitis should be to induce remission.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21615435     DOI: 10.1111/j.1365-2036.2011.04701.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  39 in total

1.  No association between the SOCS-1 -1478CA/del polymorphism and ulcerative colitis in Turkish subjects.

Authors:  Mustafa Hartavi; Selim Giray Nak; Barbaros Oral; Adem Deligönül
Journal:  Mol Biol Rep       Date:  2014-07-02       Impact factor: 2.316

2.  Assessing disease activity in patients with ulcerative colitis.

Authors:  Alissa Walsh; Simon Travis
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-11

Review 3.  Acute severe ulcerative colitis: from pathophysiology to clinical management.

Authors:  Pieter Hindryckx; Vipul Jairath; Geert D'Haens
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-01       Impact factor: 46.802

Review 4.  Psychometric validation of the SF-36® Health Survey in ulcerative colitis: results from a systematic literature review.

Authors:  Aaron Yarlas; Martha Bayliss; Joseph C Cappelleri; Stephen Maher; Andrew G Bushmakin; Lea Ann Chen; Alireza Manuchehri; Paul Healey
Journal:  Qual Life Res       Date:  2017-08-28       Impact factor: 4.147

5.  Symptom clusters in adults with inflammatory bowel disease.

Authors:  Samantha Conley; Deborah D Proctor; Sangchoon Jeon; Robert S Sandler; Nancy S Redeker
Journal:  Res Nurs Health       Date:  2017-08-17       Impact factor: 2.228

Review 6.  Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs.

Authors:  Abbi R Saniabadi; Tomotaka Tanaka; Toshihide Ohmori; Koji Sawada; Takayuki Yamamoto; Hiroyuki Hanai
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

7.  Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.

Authors:  Wing Yan Mak; Anthony Buisson; Michael J Andersen; Donald Lei; Joel Pekow; Russell D Cohen; Stacy A Kahn; Bruno Pereira; David T Rubin
Journal:  Dig Dis Sci       Date:  2018-02-22       Impact factor: 3.199

Review 8.  Role of wireless capsule endoscopy in the follow-up of inflammatory bowel disease.

Authors:  Ioannis V Mitselos; Dimitrios K Christodoulou; Konstantinos H Katsanos; Epameinondas V Tsianos
Journal:  World J Gastrointest Endosc       Date:  2015-06-10

9.  Does Medical Acceleration Improve Outcomes in Ulcerative Colitis Patients Who Are in Clinical Remission but Have Endoscopic Inflammation?

Authors:  Ji Young Chang; Jae Hee Cheon; Yehyun Park; Soo Jung Park; Tae-Il Kim; Won-Ho Kim
Journal:  Dig Dis Sci       Date:  2018-07-09       Impact factor: 3.199

10.  Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study.

Authors:  Aki Kawakami; Makoto Tanaka; Masakazu Nishigaki; Makoto Naganuma; Yasushi Iwao; Toshifumi Hibi; Hiromi Sanada; Noriko Yamamoto-Mitani; Keiko Kazuma
Journal:  J Gastroenterol       Date:  2012-12-04       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.